Recombinant Anti-Neuraminidase antibody [EPR15712] (ab197020)


  • Product name

    Anti-Neuraminidase antibody [EPR15712]
    See all Neuraminidase primary antibodies
  • Description

    Rabbit monoclonal [EPR15712] to Neuraminidase
  • Host species

  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Neuraminidase aa 50-150. The exact sequence is proprietary.
    Database link: Q99519

  • Positive control

    • HeLa whole cell lysate, Human fetal liver lysate, HepG2 whole cell lysate.
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab197020 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Detects a band of approximately 45 kDa (predicted molecular weight: 45 kDa).
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function

      Catalyzes the removal of sialic acid (N-acetylneuramic acid) moities from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex. Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl linkage.
    • Tissue specificity

      Highly expressed in pancreas, followed by skeletal muscle, kidney, placenta, heart, lung and liver. Weakly expressed in brain.
    • Involvement in disease

      Defects in NEU1 are the cause of sialidosis (SIALIDOSIS) [MIM:256550]. It is a lysosomal storage disease occurring as two types with various manifestations. Type 1 sialidosis (cherry red spot-myoclonus syndrome or normosomatic type) is late-onset and it is characterized by the formation of cherry red macular spots in childhood, progressive debilitating myoclonus, insiduous visual loss and rarely ataxia. The diagnosis can be confirmed by the screening of the urine for sialyloligosaccharides. Type 2 sialidosis (also known as dysmorphic type) occurs as several variants of increasing severity with earlier age of onset. It is characterized by the presence of abnormal somatic features including coarse facies and dysostosis multiplex, vertebral deformities, mental retardation, cherry-red spot/myoclonus, sialuria, cytoplasmic vacuolation of peripheral lymphocytes, bone marrow cells and conjunctival epithelial cells.
    • Sequence similarities

      Belongs to the glycosyl hydrolase 33 family.
      Contains 4 BNR repeats.
    • Domain

      A C-terminal internalization signal (YGTL) appears to allow the targeting of plasma membrane proteins to endosomes.
    • Post-translational

      Phosphorylation of tyrosine within the internalization signal results in inhibition of sialidase internalization and blockage on the plasma membrane.
    • Cellular localization

      Lysosome membrane. Lysosome lumen. Cell membrane. Cytoplasmic vesicle. Localized not only on the inner side of the lysosomal membrane and in the lysosomal lumen, but also on the plasma membrane and in intracellular vesicles.
    • Information by UniProt
    • Database links

    • Alternative names

      • Acetylneuraminyl hydrolase antibody
      • exo-alpha-sialidase antibody
      • G9 sialidase antibody
      • Lysosomal sialidase antibody
      • N acetyl alpha neuraminidase 1 antibody
      • N-acetyl-alpha-neuraminidase 1 antibody
      • NANH antibody
      • NEU antibody
      • NEU1 antibody
      • NEUR1_HUMAN antibody
      • Neuraminidase 1 antibody
      • Neuraminidase antibody
      • SIAL1 antibody
      • sialidase 1 (lysosomal sialidase) antibody
      • Sialidase 1 antibody
      • Sialidase, lysosomal antibody
      • Sialidase-1 antibody
      see all


    • All lanes : Anti-Neuraminidase antibody [EPR15712] (ab197020) at 1/2000 dilution

      Lane 1 : HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate
      Lane 2 : Human fetal liver lysate

      Lysates/proteins at 20 µg per lane.

      All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

      Developed using the ECL technique.

      Predicted band size: 45 kDa
      Observed band size: 45 kDa

      Exposure time: 3 minutes

      Blocking and diluting buffer was 5% NFDM /TBST

    • Anti-Neuraminidase antibody [EPR15712] (ab197020) at 1/10000 dilution + HepG2 (Human liver hepatocellular carcinoma) whole cell lysate at 20 µg

      Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

      Developed using the ECL technique.

      Predicted band size: 45 kDa
      Observed band size: 45 kDa

      Exposure time: 3 minutes


    ab197020 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab197020.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact

    Sign up